What mazdutide is
Mazdutide is a peptide that activates two receptors at once: the GLP-1 receptor and the glucagon receptor. GLP-1 is a gut hormone involved in appetite and blood sugar; glucagon is a hormone made by the pancreas. Compounds with this double action are called dual agonists. [1] [3]
It has two development codes because two companies work on it: LY3305677 is the code used by Eli Lilly and IBI362 the one used by Innovent Biologics, which develop it together. The first trial in people with overweight or obesity was published in 2021. [1] [2]
How it has been studied
Most trials so far were run in China by Innovent Biologics, in adults with overweight or obesity and in adults with type 2 diabetes; Eli Lilly ran its own phase 2 trial in the United States. The trials in the table were randomised and controlled, against placebo or against another drug of the GLP-1 class. [3] [4] [5] [6] [7] [8]
In GLORY-1, 35.7% and 49.5% of participants on the two doses had lost at least 15% of their body weight at week 48, against 2.0% on placebo. In the US trial the largest dose gave the largest reduction, but one participant in five in that group stopped treatment because of adverse events, mostly gastrointestinal. [4] [8]
| Trial | Who took part | Length | Main published result |
|---|---|---|---|
| Phase 2, China (2023) | 248 adults with overweight or obesity | 24 weeks | Mean body-weight change of -6.7% to -11.3% across doses, against +1.0% with placebo [3] |
| Phase 3 GLORY-1, China (2025) | 610 adults with overweight or obesity | 48 weeks | Mean body-weight change of -11.0% and -14.0% with the two doses, against +0.3% with placebo [4] |
| Phase 3 GLORY-2, China (2026) | 461 adults with obesity, 16% of them with type 2 diabetes | 60 weeks | Mean body-weight change of -16.7% with a higher dose, against -1.5% with placebo [5] |
| Phase 3 against placebo, type 2 diabetes, China (2026) | 320 adults whose diabetes was not controlled by diet and exercise alone | 24 weeks, then an extension | HbA1c fell by 1.57 and 2.15 percentage points with the two doses, against 0.14 with placebo [6] |
| Phase 3 against dulaglutide, type 2 diabetes, China (2026) | 731 adults already on oral diabetes medicines | 28 weeks | Larger falls in HbA1c and in body weight than with dulaglutide, a GLP-1 receptor agonist [7] |
| Phase 2, United States (2026) | 179 adults with obesity or overweight, without diabetes | 48 weeks | Mean body-weight change at week 32 of -7.3% to -18.1% across doses, against -0.9% with placebo [8] |
Safety findings reported so far
In all these trials the most common adverse events were gastrointestinal, such as nausea, diarrhoea and vomiting, and most were mild to moderate. In GLORY-1, adverse events led to stopping treatment in 1.5% and 0.5% of participants on the two doses and in 1.0% on placebo. [4] [6] [7]
With the higher dose tested in GLORY-2, vomiting was reported by 53.1% of participants against 1.3% on placebo, nausea by 46.9% against 3.2% and diarrhoea by 39.4% against 6.5%; 2.9% stopped treatment because of adverse events, against none on placebo. [5]
Regulatory status (November 2026)
Mazdutide received its first approval in China in June 2025, for long-term weight management in adults with obesity or overweight; in September 2025 it was also approved in China for blood sugar control in adults with type 2 diabetes. It is also being studied in fatty liver disease, obstructive sleep apnoea and alcohol use disorder. [1]
In the United States it is still investigational: Eli Lilly's phase 2 trial there is completed and was published in 2026. Research material is not a medicine: it has not been reviewed for safety, effectiveness or quality in people and must not be used in people. We sell mazdutide only for in vitro laboratory research, without instructions for use. [8]
What is being studied now
Innovent Biologics has registered further phase 3 trials on ClinicalTrials.gov: one comparing mazdutide with semaglutide in adults with overweight or obesity and fatty liver disease, one in adolescents with obesity or overweight and one in people with high blood pressure and overweight or obesity. [9] [10] [11]
Storage and stability in the lab
Peptides can degrade through chemical routes such as oxidation, deamidation and hydrolysis and through physical routes such as aggregation, and they are generally more stable in the dry state than in solution. [12]
Lyophilised vials are therefore normally kept cold, dry and away from light until they are used. The storage statement on the product page and on the batch certificate takes precedence.
How to check a batch
A useful certificate of analysis names the testing laboratory, the batch number printed on the vial, the test date and the methods used. Identity is usually confirmed by mass spectrometry, where the measured mass should match the expected molecular mass, and purity is measured by HPLC.
Where the manufacturer supplies a batch report, we link it on the product page; products without one do not claim one.
Perguntas frequentes
What do the codes IBI362 and LY3305677 mean?
They are the development codes of mazdutide: LY3305677 is the one used by Eli Lilly and IBI362 the one used by Innovent Biologics, which develop it together. [1] [2]
Is mazdutide approved?
In China, yes: since June 2025 for weight management in adults with obesity or overweight and since September 2025 for type 2 diabetes. In the United States it is still investigational. [1] [8]
How is mazdutide different from semaglutide?
Semaglutide acts on the GLP-1 receptor; mazdutide acts on the GLP-1 and on the glucagon receptor. A phase 3 trial in China compares the two in adults with overweight or obesity and fatty liver disease. [9]
What did the phase 3 trials in obesity show?
In GLORY-1, mean body weight fell by 11.0% and 14.0% with the two doses after 48 weeks, against a 0.3% gain with placebo; in GLORY-2 it fell by 16.7% with a higher dose after 60 weeks, against 1.5% with placebo. [4] [5]
Can I buy mazdutide for personal use?
No. Everything we sell is for in vitro laboratory research by adults aged 21 or over. It is not for use in people or animals, and we give no advice on use or dosing.
Este guia resume pesquisas publicadas e informações regulatórias. Não é aconselhamento médico. Tudo o que vendemos é somente para pesquisa de laboratório in vitro, por adultos de 21 anos ou mais, e não para uso em pessoas ou animais.
Fontes
- Shirley M. Mazdutide: First Approval. Drugs. 2025 (PubMed 41028652)
- Ji L et al. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine. 2021 (PubMed 34430840)
- Ji L et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023 (PubMed 38092790)
- Ji L et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). N Engl J Med. 2025 (PubMed 40421736)
- Gao L et al. The GLORY-2 randomized clinical trial of mazdutide for weight reduction in Chinese adults with obesity. JAMA. 2026;336(5):377-388 (PubMed 42251595)
- Zhu D et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026 (PubMed 41407859)
- Guo L et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026 (PubMed 41407860)
- Hsia SH et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet Diabetes Endocrinol. 2026 (PubMed 42628555)
- ClinicalTrials.gov NCT06884293: A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) (phase 3)
- ClinicalTrials.gov NCT07255209: A Study of IBI362 in Chinese Adolescents With Obesity or Overweight (phase 3)
- ClinicalTrials.gov NCT07469800: Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity (phase 3)
- Manning MC et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010 (PubMed 20143256)